These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10342310)

  • 1. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
    Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients.
    Birkeland SA
    Transplantation; 2001 Apr; 71(8):1089-90. PubMed ID: 11374407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation.
    Birkeland SA; Bendtzen K; Møller B; Hamilton-Dutoit S; Andersen HK
    Transplantation; 1999 Mar; 67(6):876-81. PubMed ID: 10199737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.
    Darenkov IA; Marcarelli MA; Basadonna GP; Friedman AL; Lorber KM; Howe JG; Crouch J; Bia MJ; Kliger AS; Lorber MI
    Transplantation; 1997 Sep; 64(6):848-52. PubMed ID: 9326409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy.
    Birkeland SA
    Transplantation; 1998 Nov; 66(9):1207-10. PubMed ID: 9825819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV.
    Birkeland SA; Andersen HK; Gahrn-Hansen B
    Scand J Infect Dis; 1998; 30(3):221-6. PubMed ID: 9790127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M; Carl S
    J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K; Kim SI; Moon JI; Kim YS; Kim MS
    Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
    Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
    Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
    Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
    Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
    Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.